The transport of opioid analgesics across the blood-brain barrier (BBB) is an important determinant of their therapeutic eŠects. The human brain is protected by the BBB, which consists of brain capillary endothelial cells linked with tight junctions. It is well established that the polarized expression of numerous transporters and receptors at the brain capillary endothelial cells controls the blood-brain exchange of nutrients, waste products deriving from neurotransmitter substances, and drugs. Morphine is a substrate of P-glycoprotein and the P-glycoprotein-mediated eOEux transport at the BBB maintains a lower unbound concentration of morphine in the brain compared with plasma. On the other hand, oxycodone has 3 times higher unbound concentration in the brain than plasma, suggesting an active transport mechanism of oxycodone across the BBB into the brain. In vitro transport study using BBB model cells showed that oxycodone is e‹ciently transported by a proton-coupled organic cation antiporter. Human BBB model cells also retain the protoncoupled organic cation antiporter. Although adjuvant analgesics include many cationic drugs that interact with oxycodone transport across the BBB at relatively high concentrations, these drugs would enhance the antinociceptive eŠects of oxycodone with little eŠect on oxycodone pharmacokinetics, including brain distribution at therapeutically or pharmacologically relevant concentrations. Theseˆndings support the idea that proton-coupled organic cation antiportermediated transport of oxycodone at the BBB plays a role in determining the therapeutic e‹cacy of this opioid analgesic drug.
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Fig. 1. Oxycodone and Morphine Transport across the Blood-Brain Barrier
Oxycodone is actively transported across the blood-brain barrier into the brain by a proton-coupled organic cation antiporter (H ＋ /OC ＋ antiporter), in contrast to the P-glycoprotein-meditated brain-to-blood eOEux transport of morphine. 
